Objective:

To address the limitations of current drug testing methods, such as high failure rates and ethical concerns, and promote the industrialization of organoid technologies for better predictability in drug development.

Key Findings:

• Over 90% of drug candidates that pass animal testing fail in human trials, indicating a significant predictability gap and the need for better models.
• The FDA Modernization Act allows for the use of organoids in regulatory submissions, phasing out animal testing and paving the way for innovative approaches.
• The UK is leading in NAMs with dedicated funding and the establishment of the UK Centre for the Validation of Alternative Methods, setting a precedent for regulatory frameworks.
• Current organoid science lacks standardization, leading to variability and challenges in reproducibility, which must be addressed for effective implementation.
• Innovative reprogramming and high-density cell banking can enhance the quality and consistency of iPSCs for organoid development, reducing genetic instability.

Interpretation:

The transition to organoid technologies presents a promising avenue for improving drug development predictability and enhancing personalized medicine, but requires a concerted effort to standardize practices and establish a supportive regulatory environment.

Limitations:

• The FDA has not provided a clear regulatory framework for NAMs, creating uncertainty for developers and hindering progress.
• The variability in current organoid science hampers reproducibility and comparability across studies, complicating validation efforts.
• Existing iPSC reprogramming methods lead to genetic instability and loss of function, complicating their use in therapies and affecting patient outcomes.

Conclusion:

By addressing standardization and regulatory challenges, organoid technology could revolutionize personalized medicine, allowing for more effective and targeted drug development, ultimately improving patient outcomes.